Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 14
- Publication type:
- Article
Works matching IS 21534888 AND DT 2020 AND VI 11 AND IP 1
Results: 30
1
2
Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 14
- By:
- Publication type:
- Article
3
Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 13
- By:
- Publication type:
- Article
4
Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 12
- Publication type:
- Article
5
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 9
- By:
- Publication type:
- Article
6
Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 23
- Publication type:
- Article
7
ELEVATE TN: Interim Results of a Phase 3 Study of Acalabrutinib in Treatment-Naïve Patients with CLL.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 23
- Publication type:
- Article
8
Ibrutinib plus Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of the Phase 3 E1912 Trial.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 22
- Publication type:
- Article
9
Ibrutinib plus Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 22
- Publication type:
- Article
10
Surgery for Cholangiocarcinoma: Highlights from the First Annual Cholangiocarcinoma Summit, October 2019.
- Published in:
- 2020
- Publication type:
- Proceeding
11
Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 19
- By:
- Publication type:
- Article
12
Real-World Evidence Supports Patient Navigation in Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 17
- Publication type:
- Article
13
Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 17
- By:
- Publication type:
- Article
14
Split-Fill Program for Oncology Oral Medications Is Cost-Saving.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 15
- Publication type:
- Article
15
Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 15
- By:
- Publication type:
- Article
16
Venetoclax plus Intensive Chemotherapy Shows Promising Results in All Patients with Acute Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 12
- By:
- Publication type:
- Article
17
Keytruda Indicated for BCG-Unresponsive High-Risk, Non-Muscle Invasive Bladder Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 11
- Publication type:
- Article
18
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 11
- By:
- Publication type:
- Article
19
Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 10
- By:
- Publication type:
- Article
20
Padcev, a Novel Targeted Therapy, FDA Approved for Advanced or Metastatic Urothelial Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 9
- Publication type:
- Article
21
Lynparza Indicated for Maintenance Treatment of Metastatic Pancreatic Cancer with BRCA Mutation.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 11
- Publication type:
- Article
22
Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 8
- By:
- Publication type:
- Article
23
Enhertu, a Dual-Targeted Therapy, Approved for Metastatic HER2-Positive Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 7
- Publication type:
- Article
24
Ayvakit First Targeted Therapy Approved for Gastrointestinal Stromal Tumors with PDGFRA Mutation.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 7
- Publication type:
- Article
25
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 7
- By:
- Publication type:
- Article
26
Tazverik First FDAApproved Drug for Advanced Epithelioid Sarcoma Ineligible for Resection.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 6
- Publication type:
- Article
27
First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 1
- By:
- Publication type:
- Article
28
Mosunetuzumab, a Dual- Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 1
- By:
- Publication type:
- Article
29
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 1
- By:
- Publication type:
- Article
30
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 1, p. 1
- By:
- Publication type:
- Article